Australian Therapeutic Pipeline to translate health discoveries into clinical application

Therapeutic Innovation Australia (TIA) has launched the Australian Therapeutic Pipeline - a collaborative initiative to better enable Australian researchers to translate their health discoveries into clinical application. The initiative was launched by Ditta Zizi, branch manager, Research and Higher Education Infrastructure of the Australian Government Department of Education, as part of TIA’s 2nd National Translational Health Capability Symposium in Brisbane.

Australia produces almost twice the amount of citeable research per capita as the United States, yet we also have one of the lowest rates in conversion of these discoveries into patents and limited success in bringing new treatments through to patients. Reasons for this poor productivity are said to relate to a lack of connectivity and commercial expertise.

The Australian Therapeutic Pipeline will consist of state-of-the-art facilities that support therapeutic product development. The pipeline will provide pathways for researchers developing new biopharmaceuticals, cell therapies, diagnostics and personalised medicines. It will also interact with TIA’s expert ‘Virtual Pharma’ committee, which will provide commercial expertise freely to Australian public sector researchers.

TIA’s translational health consortium will form the core of the pipeline, and TIA welcomes contact from other organisations providing high-quality translational research infrastructure. For more information, contact TIA CEO Dr Stewart Hay at stewart.hay@therapeuticinnovation.com.au or phone 0428 658 282.